Ilaris real-world study for periodic fevers and sJIA
Part of Blood & lymphatic, Bones, joints & muscles, Brain & nervous system, Genetic & congenital, Hormones & metabolism, Immune system & allergy, Skin clinical trials.
This study watches how people with certain periodic fever syndromes or a severe type of childhood arthritis (sJIA) do on the medicine Ilaris during their regular doctor visits. It collects information to see how well the medicine works in everyday care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have one of these inflammatory conditions: CAPS, crFMF, TRAPS, HIDS/MKD (for adults or children 2+), or sJIA (for children 2 to 18 years old)
- You are either already taking Ilaris (canakinumab) as part of your regular care, or you and your doctor have agreed to start it
- You are not taking Ilaris for another autoimmune disease (like rheumatoid arthritis or lupus)
- You are not currently in another research study that changes how your condition is treated
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at children with systemic juvenile idiopathic arthritis (sJIA), a type of arthritis that causes joint swelling, fever, and rash. The goal is to learn more about the disease and how it's treated to improve care.
This study looks at two substances in the blood (IL-18 and IL-18BP) to see if they can help doctors tell apart different causes of fever and inflammation in children. It might help find better ways to diagnose conditions like juvenile idiopathic arthritis and autoinflammatory diseases.
This trial studies sarilumab, a targeted medicine, to help reduce symptoms in children and teens with systemic juvenile idiopathic arthritis (sJIA) who have not responded enough to current treatments. You may be considered because the study looks at how well and safely repeated doses work in pediatric patients.
This is a long-term study that collects health information and lab samples from people who have certain diagnoses of recurring (coming and going) inflammatory fevers and related joint or immune conditions. It may help researchers better understand these diseases and how they work over time.
This Phase 3 trial studies how well upadacitinib (a pill) and tocilizumab (a shot/IV medicine) improve symptoms and inflammation in children with active systemic juvenile idiopathic arthritis (sJIA). It also looks at side effects and how these medicines move through the body.
This study creates a personalized medicine network to better understand and treat childhood arthritis. If you have JIA or unexplained joint inflammation, researchers will look at your biology to find the best treatment approach for you.
Hear when a new Systemic Juvenile Idiopathic Arthritis (sJIA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.